Alliance Pharmaceutical Corp.

Novartis Ag

Nektar Therapeutics

Respira Therapeutics, Inc.

Other

Inhale Therapeutic Systems, Inc.

Imcor Pharmaceutical Company

Novartis Pharma Ag

University of Illinois

Cystetic Medicines, Inc.

Jeffry G Weers

Thomas E Tarara

Ernest George Schutt

Luis A Dellamary

Alexey S Kabalnov

David H Klein

Charles David Anderson

David P Evitts

Rene Alta Kinner

Jean G Riess

Nicholas Simon Faithfull

Leo A Trevino

Zhen Xu

Martin J Donovan

Robert Curtis

Hugh Smyth

Revati Shreeniwas

Adaani Frost

Cindy Shizuko Johnson

Alain Romero

Daniel Huang

Nagaraja P Rao

Michael Steven Hartman

Danforth Miller

Geraldine Venthoye

Patrick Teung

Helen M Ranney

Martin D Burke

Lorraine E Reeve

Andrew Clark

Michael A Eldon

Dan Deaton

Peter E Keipert

James Hannon

Stephen G Flore

Keith Ung

Trixie Tan

Adrian I Bot

Alexev Kabalnov

Leo Chan

Timothy J Pelura

Danforth P Miller

Maria Geraldine Venthoye

Thomas Tarara

Jean Reiss

Corinne Soutar

Agnieszka Lewandowska

Rangachari Narashimhan

Shirley Lyons

Try Keith Ung

Disclosed are pharmaceutical compositions, comprising: (i) amphotericin B or a pharmaceutically acceptable salt or hydrate thereof; (ii) cholesterol; (iii) phospholipids, comprising hydrogenated soy phosphatidylcholine and distearoylphosphatidylglycerol; and (iv) calcium chloride (CaCl)). Also disclosed are methods of using the pharmaceutical compositions for treating a disease or disorder (e.g., cystic fibrosis), increasing the pH of airway surface liquid, increasing bicarbonate secretion into airway surface liquid, and increasing a subject's forced expiratory volume in one second.

Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin B

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Methods for treatment of pulmonary hypertension

Embodiments of the invention relate to particulate agents and compositions comprising particulate agents for inhalation, and methods for preparing such particulate agents and compositions for inhalation, as well as therapeutic methods. Embodiments of the method comprise preparing an emulsion by combining an oil phase dispersion of hydrophobic seed particles and an aqueous dispersion comprising an emulsifier and an emulsion stabilizer and preparing a feedstock comprising encapsulated particles by homogenizing the emulsion, and forming a plurality of coated particles by spray drying the feedstock, wherein resulting particles comprises a porous shell disposed on or over a core and the core comprises at least one hydrophobic seed particle.

Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients

A powder aerosolization apparatus comprises a housing comprising an outlet adapted to be inserted into a user's mouth and one or more bypass air openings. A receptacle support within the housing supports a receptacle containing a powder pharmaceutical formulation. A puncturing mechanism within the housing creates in the receptacle one or more inlet openings and one or more powder outflow openings, wherein the powder outflow openings have a total area of from 0.2 mmto 4.0 mm. Upon a user's inhalation through the outlet, air flows through the one or more bypass air openings and through the receptacle to aerosolize the powder pharmaceutical formulation in the receptacle. In one version, the relative flow parameters between the flow through the one or more bypass openings and the one or more powder outflow openings are selected so that flow of aerosolized pharmaceutical formulation does not occur until a predetermined inhalation flow rate is achieved.

Aerosolization apparatus for inhalation profile-independent drug delivery

Embodiments of the present invention provide a dry powder composition comprising porous carrier particles associated with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodiments of the present invention further comprise a spray-drying process to create the respirable agglomerates. Embodiments of the present invention further relate to the use of the dry powder formulation comprising respirable agglomerates for the treatment of a patient having a disease or condition which is treatable thereby.

Respirable agglomerates of porous carrier particles and micronized drug

Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.

Phospholipid-based powders for drug delivery

The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.

Pulmonary delivery of aminoglycoside

A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic diameter from about 1 &#x3bc;m to about 5 &#x3bc;m, and the fluoroquinolone has a half life in the lungs of at least 1.5 hours. The composition is useful in treating an endobronchial infection, such as, and is particularly useful in treating cystic fibrosis.

Pulmonary delivery of a fluoroquinolone

Dry powder formulations for inhalation comprising spray-dried particles and their use in the treatment of an obstructive or inflammatory airways disease. Each particle has a core of a first active ingredient in substantially crystalline form that is coated with a layer of a second active ingredient in substantially amorphous form that is dispersed in a pharmaceutically acceptable hydrophobic excipient. A process for preparing such formulations is also described.

Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases

A microparticle for drug delivery comprises an active agent and an excipient, the excipient comprising a metal ion-lipid complex. The metal ion is chosen from the group consisting of lanthanide metals, actinide metals, group IIa and IIIb metals, transition metals or mixtures thereof. The lipid comprises a phospholipid. The complex results in a glass transition temperature increase of the microparticle.

Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery

Growing community of inventors

San Diego, CA, United States of America

Jeffry G Weers